Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Most multiple myeloma patients have low testosterone.
John S, Sharma N, Sborov DW, Williams N, Jones D, Benson DM, Efebera YA, Rosko AE, Vincent J, Hofmeister CC. John S, et al. Among authors: efebera ya. Leuk Lymphoma. 2019 Mar;60(3):836-838. doi: 10.1080/10428194.2018.1508664. Epub 2018 Oct 2. Leuk Lymphoma. 2019. PMID: 30277092 Free PMC article. No abstract available.
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.
Bolaños-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, Elmariah H, Rezvani AR, Gooptu M, Larkin KT, Shaffer BC, El Jurdi N, Loren AW, Solh M, Hall AC, Alousi AM, Jamy OH, Perales MA, Yao JM, Applegate K, Bhatt AS, Kean LS, Efebera YA, Reshef R, Clark W, DiFronzo NL, Leifer E, Horowitz MM, Jones RJ, Holtan SG; BMT CTN 1703 Investigators. Bolaños-Meade J, et al. Among authors: efebera ya. N Engl J Med. 2023 Jun 22;388(25):2338-2348. doi: 10.1056/NEJMoa2215943. N Engl J Med. 2023. PMID: 37342922 Free PMC article. Clinical Trial.
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.
Benson DM Jr, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, Greenfield CN, Porcu P, Devine SM, Rotem-Yehudar R, Lozanski G, Byrd JC, Caligiuri MA. Benson DM Jr, et al. Blood. 2010 Sep 30;116(13):2286-94. doi: 10.1182/blood-2010-02-271874. Epub 2010 May 11. Blood. 2010. PMID: 20460501 Free PMC article.
Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning.
Hamadani M, Craig M, Phillips GS, Abraham J, Tse W, Cumpston A, Gibson L, Remick SC, Bunner P, Leadmon S, Elder P, Hofmeister C, Penza S, Efebera Y, Andritsos L, Garzon R, Benson DM Jr, Blum W, Devine SM. Hamadani M, et al. Hematol Oncol. 2011 Dec;29(4):202-10. doi: 10.1002/hon.985. Epub 2011 Feb 28. Hematol Oncol. 2011. PMID: 21360728 Free PMC article.
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.
Benson DM Jr, Bakan CE, Zhang S, Collins SM, Liang J, Srivastava S, Hofmeister CC, Efebera Y, Andre P, Romagne F, Bléry M, Bonnafous C, Zhang J, Clever D, Caligiuri MA, Farag SS. Benson DM Jr, et al. Blood. 2011 Dec 8;118(24):6387-91. doi: 10.1182/blood-2011-06-360255. Epub 2011 Oct 26. Blood. 2011. PMID: 22031859 Free PMC article.
Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.
Dunavin NC, Wei L, Elder P, Phillips GS, Benson DM Jr, Hofmeister CC, Penza S, Greenfield C, Rose KS, Rieser G, Merritt L, Ketcham J, Heerema N, Byrd JC, Devine SM, Efebera YA. Dunavin NC, et al. Among authors: efebera ya. Leuk Lymphoma. 2013 Aug;54(8):1658-64. doi: 10.3109/10428194.2012.751528. Epub 2012 Dec 31. Leuk Lymphoma. 2013. PMID: 23194056 Free PMC article.
Characterization of multiple myeloma vesicles by label-free relative quantitation.
Harshman SW, Canella A, Ciarlariello PD, Rocci A, Agarwal K, Smith EM, Talabere T, Efebera YA, Hofmeister CC, Benson DM Jr, Paulaitis ME, Freitas MA, Pichiorri F. Harshman SW, et al. Among authors: efebera ya. Proteomics. 2013 Oct;13(20):3013-29. doi: 10.1002/pmic.201300142. Proteomics. 2013. PMID: 23983189 Free PMC article.
Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.
Collins SM, Bakan CE, Swartzel GD, Hofmeister CC, Efebera YA, Kwon H, Starling GC, Ciarlariello D, Bhaskar S, Briercheck EL, Hughes T, Yu J, Rice A, Benson DM Jr. Collins SM, et al. Among authors: efebera ya. Cancer Immunol Immunother. 2013 Dec;62(12):1841-9. doi: 10.1007/s00262-013-1493-8. Epub 2013 Oct 26. Cancer Immunol Immunother. 2013. PMID: 24162108 Free PMC article.
119 results